(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 April 2014 (03.04.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/052678 A1

(51) International Patent Classification:
A61K 9/08 (2006.01) *A61K 47/36* (2006.01)
A61K 31/437 (2006.01) *A61K 47/38* (2006.01)
A61K 47/34 (2006.01)

(21) International Application Number:
PCT/US2013/062051

(22) International Filing Date:
26 September 2013 (26.09.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/705,943 26 September 2012 (26.09.2012) US
61/773,032 5 March 2013 (05.03.2013) US

(71) Applicants: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 & Province Line Road, Princeton, NJ 08543-4000 (US). **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventor: **BADAWY, Sherif, Ibraham, Farag**; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543-4000 (US).

(74) Agents: **OKUN, Jason, M.** et al.; Fitzpatrick, Cella, Harper & Scinto, 1290 Avenue of the Americas, New York, NY 10104-3800 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

(54) **Title**: APIXABAN LIQUID FORMULATIONS

Fig. 3

Study 1: Mean apixaban plasma concentration-time profile (error bars show +1 standard deviation).



A= apixaban 2 x 5 mg Phase 3 tablets

B = apixaban 25 mL x 0.4 mg/mL liquid formulation

(57) **Abstract**: Apixaban liquid formulation is provided. Also provided is a method of administering an apixaban liquid formulation.

WO 2014/052678 A1